Pharmaceutical Fine Chemicals Market Research Report: By Drug Type, Product, Application - Global Industry Analysis and Growth Forecast to 2030
発行: Prescient & Strategic Intelligence Private Limited
ページ情報: 英文 206 Pages
世界の医薬品ファインケミカル市場は、2019年に1,003億米ドルとなりました。同市場は、予測期間中（2020年～2030年）に6.2％のCAGRで成長する見通しです。同市場の主な成長要因には、急増する老年人口と、アジア太平洋地域（APAC）地域における製薬業界の急速な拡大が挙げられます。the United Nations Department of Economic and Social Affairsによる最新の世界人口高齢化レポートによると、65歳以上の人々の数は2050年までに15億人に増加すると予想されています。高齢者は体力や免疫の弱さにより成人・子供よりも病気にかかりやすく、医薬品の必要性が高くなっており、薬品を製造するための化学物質の必要性がさらに高まっています。また、同市場において、北米が主な収益シェアを占めています。同地域の製薬業界が一番大きく、ヘルスケア費の高額化が進んでいるためです。これに加え、同地域の各製薬会社は、現在治療不可能な疾患の増加に対応するための医薬品を開発するために調査開発活動を進めています。
Pharmaceutical Fine Chemicals Market Research Report: By Drug Type (Proprietary, Non-Proprietary), Product (Basic Building Blocks, Advanced Intermediates, Active Ingredients), Application (Cardiovascular, Neurological, Oncological, Respiratory, Gastrointestinal, Musculoskeletal) - Global Industry Analysis and Growth Forecast to 2030.
The global pharmaceutical fine chemicals market generated a revenue of $100.3 billion in 2019, and it is predicted to grow at a 6.2% CAGR during the forecast period (2020-2030). The major driving factors of the market are the surging geriatric population, and rapid expansion of the pharmaceutical industry in the Asia-Pacific (APAC) region. In terms of drug type, the pharmaceutical fine chemicals market is bifurcated into non-proprietary and proprietary, between which, the proprietary drug bifurcation accounted for the larger revenue share of the market.
This is because of the fact that the production of these drugs requires high capital investment, compliance to stringent regulations, strong research & development efforts, and adequate quality control measures. On the basis of product, the pharmaceutical fine chemicals market is categorized into active ingredients, basic building blocks, and advanced intermediaries. Out of these, the active ingredients category is predicted to advance at the fastest pace during the forecast period. These are the most important component of the drug, since they accomplish the purpose of medication, owing to which, their demand is predicted to increase.
The surging aging population is one of the major driving factors of the pharmaceuticals fine chemicals market. According to the latest World Population Ageing report by the United Nations Department of Economic and Social Affairs, the number of people aged 65 and above is expected to increase to 1.5 billion by 2050. Because of their physical weakness and immunocompromised nature, aged people fall sick more often than adults and children, which is why, the need for medical drugs is higher for them. This is further creating the need for chemicals to produce drugs.
The growing awareness in Africa is expected to open up wide opportunities for players operating in the pharmaceuticals fine chemical market. The governments of various countries in the region, such as Nigeria and Kenya, are encouraging the local production of medical drugs, which is primarily aimed at improving the accessibility of these products. Countries in the region are further focusing on enhancing the public health and aiming to have a larger and healthier workforce for the benefit of national economy. These aspects are projected to result in the growth of the market.
When application is taken into consideration, the pharmaceutical fine chemicals market is divided into musculoskeletal, cardiovascular, gastrointestinal, neurological, respiratory, and oncological. The largest revenue share of the market during the forecast period is predicted to be held by the cardiovascular division. This is due to the growing prevalence of cardiovascular diseases, such as hypertension, stroke, coronary artery disease, and arrhythmias. This is leading to the increasing demand for heart medication, which, in turn, is driving the demand for pharmaceutical fine chemicals.
Geographically, North America accounted for the major revenue share of the pharmaceutical fine chemicals market during the historical period (2014-2019). This is because of the fact that the region has the largest pharmaceutical industry in the region and further accounts for increased high healthcare expenditure. In addition to this, various drug manufacturers in the region are pursuing research & development activities for coming up with medication for the rising number of presently-untreatable diseases.